<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90706">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887353</url>
  </required_header>
  <id_info>
    <org_study_id>1024475</org_study_id>
    <nct_id>NCT01887353</nct_id>
  </id_info>
  <brief_title>The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure</brief_title>
  <acronym>RAD HF</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of
      recurrent atrial fibrillation in post-cardioversion patients with heart failure and
      preserved ejection fraction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first AF recurrence</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Patients will take ranolazine 1000 mg tablets twice daily</description>
    <arm_group_label>Ranolazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female &gt; 18 years of age;

          -  Documentation of heart failure and who are in NYHA class II or III;

          -  Documented history of symptomatic AF &lt; 6 months in duration at the time of
             presentation, currently in AF at the time of the external electrical cardioversion,
             and successfully restored to normal sinus rhythm;

          -  Percutaneous coronary intervention (PCI) patients who can be placed on
             anticoagulation with warfarin post-cardioversion (and not on rivaroxaban or
             dabigatran);

          -  Demonstration of preserved ejection fraction (EF) by echocardiography;

          -  Echocardiographic evidence of impaired diastolic filling.

        Exclusion Criteria:

          -  Known history of permanent or long-standing AF (&gt; 6 months);

          -  Other acutely reversible causes of AF, including but not limited to: hyperthyroidism,
             pericarditis, myocarditis or pulmonary embolism;

          -  Known history of cirrhosis;

          -  NYHA Class IV;

          -  Myocardial Infarction, unstable angina, or coronary artery bypass graft surgery
             within three months prior to screening;

          -  Percutaneous coronary intervention (PCI) within 4 weeks prior to screening, if these
             patients need to be placed on rivaroxaban or dabigatran post-cardioversion;

          -  Clinically significant valvular disease;

          -  Clinically significant pulmonary disease;

          -  Stroke within 3 months prior to screening;

          -  Creatinine clearance &lt; 30 mL/min as calculated by Cockcroft-Gault formula;

          -  Use of anti-arrhythmic drugs (Class Ia or IIIc) within 3 months prior to screening;

          -  Concurrent use of drugs considered strong inhibitors of CYP3A;

          -  Concurrent use of drugs considered as CYP3A inducers;

          -  Prior treatment with ranolazine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T. Jared Bunch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>T. Jared Bunch, MD</last_name>
    <phone>801-507-4701</phone>
    <email>Jared.Bunch@imail.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patti Spencer</last_name>
    <phone>801-507-4778</phone>
    <email>Patti.Spencer@imail.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107-5701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Jared Bunch, MD</last_name>
      <phone>801-507-4701</phone>
      <email>Jared.Bunch@imail.org</email>
    </contact>
    <investigator>
      <last_name>T. Jared Bunch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Crandall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John D Day, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pete Weiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Osborn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Mallendar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>heart failure</keyword>
  <keyword>ranolazine</keyword>
  <keyword>cardioversion</keyword>
  <keyword>persistent AF</keyword>
  <keyword>paroxysmal AF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
